{"organizations": [], "uuid": "beae42878cce3b9843cf7283dbd49d2b56e19fba", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180125.html", "section_title": "Archive News &amp; Video for Thursday, 25 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biogen-inc-reports-qtrly-loss-per/brief-biogen-inc-reports-qtrly-loss-per-share-of-1-40-idUSASB0C2A2", "country": "US", "domain_rank": 408, "title": "BRIEF-Biogen Inc Reports Qtrly Loss Per Share Of $1.40", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.989, "site_type": "news", "published": "2018-01-25T19:36:00.000+02:00", "replies_count": 0, "uuid": "beae42878cce3b9843cf7283dbd49d2b56e19fba"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biogen-inc-reports-qtrly-loss-per/brief-biogen-inc-reports-qtrly-loss-per-share-of-1-40-idUSASB0C2A2", "ord_in_thread": 0, "title": "BRIEF-Biogen Inc Reports Qtrly Loss Per Share Of $1.40", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-biogen inc", "sentiment": "negative"}, {"name": "biogen inc", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 25 (Reuters) - Biogen Inc:\n* BIOGEN REPORTS RECORD REVENUES FOR BOTH THE FULL YEAR AND FOURTH QUARTER OF 2017, $12.3 BILLION AND $3.3 BILLION, RESPECTIVELY\n* 2018 FULL YEAR REVENUE GUIDANCE OF $12.7 TO $13.0 BILLION\n* 2017 GAAP EPS DECREASED 30%, INCLUDING A $1.2 BILLION CHARGE DUE TO U.S. TAX REFORM\n* QTRLY ‍NON-GAAP DILUTED EPS $5.26​ * QTRLY LOSS PER SHARE $1.40 * QTRLY PLEGRIDY REVENUE OF $125​ MILLION VERSUS. $125 MILLION\n* QTRLY TYSABRI REVENUE OF $463​ MILLION VERSUS. $474 MILLION\n* GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $22.20 AND $23.20 FOR 2018\n* QTRLY TECFIDERA REVENUE OF $1,076 MILLION VERSUS. $1,002 MILLION\n* NON-GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $24.20 AND $25.20 FOR 2018\n* QTRLY AVONEX REVENUE OF $520 MILLION VERSUS. $564 MILLION\n* FY2018 EARNINGS PER SHARE VIEW $24.16, REVENUE VIEW $12.68 BILLION -- THOMSON REUTERS I/B/E/S\n* Q4 EARNINGS PER SHARE VIEW $5.45, REVENUE VIEW $3.08 BILLION -- THOMSON REUTERS I/B/E/S\n* QTRLY TOTAL REVENUES $3,307 MILLION VERSUS $2,872 MILLION LAST YEAR\n* ‍IN Q4 CO BOOKED A GAAP & NON-GAAP TAX CHARGE OF $42 MILLION & $50 MILLION, RESPECTIVELY, RELATED TO IMPAIRMENT OF ZINBRYTA RELATED TAX ASSETS​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-25T19:36:00.000+02:00", "crawled": "2018-01-26T21:12:53.028+02:00", "highlightTitle": ""}